Study Protocol, Sample Characteristics, and Loss to Follow-Up: The OPPERA Prospective Cohort Study - 25/11/13

Abstract |
When studying incidence of pain conditions such as temporomandibular disorder (TMD), repeated monitoring is needed in prospective cohort studies. However, monitoring methods usually have limitations and, over a period of years, some loss to follow-up is inevitable. The OPPERA prospective cohort study of first-onset TMD screened for symptoms using quarterly questionnaires and examined symptomatic participants to definitively ascertain TMD incidence. During the median 2.8-year observation period, 16% of the 3,263 enrollees completed no follow-up questionnaires, others provided incomplete follow-up, and examinations were not conducted for one third of symptomatic episodes. Although screening methods and examinations were found to have excellent reliability and validity, they were not perfect. Loss to follow-up varied according to some putative TMD risk factors, although multiple imputation to correct the problem suggested that bias was minimal. A second method of multiple imputation that evaluated bias associated with omitted and dubious examinations revealed a slight underestimate of incidence and some small biases in hazard ratios used to quantify effects of risk factors. Although “bottom line” statistical conclusions were not affected, multiply-imputed estimates should be considered when evaluating the large number of risk factors under investigation in the OPPERA study.
Perspective |
These findings support the validity of the OPPERA prospective cohort study for the purpose of investigating the etiology of first-onset TMD, providing the foundation for other papers investigating risk factors hypothesized in the OPPERA project.
Le texte complet de cet article est disponible en PDF.Key words : Temporomandibular disorder, cohort studies, population statistics, epidemiologic methods, proportional hazards models
Plan
| Publication of this supplement was made possible with support of the National Institutes of Health grant U01DE017018 and T32ES007018. The OPPERA program also acknowledges resources specifically provided for this project by the participating institutions: Battelle Memorial Institute; University at Buffalo; University of Florida; University of Maryland; University of North Carolina at Chapel Hill. |
|
| R.B.F. and G.D.S. are consultants and equity stock holders, and W.M. and L.D. are cofounders and equity stock holders in Algynomics, Inc, a company providing research services in personalized pain medication and diagnostics. Other authors declare no conflicts of interest. |
|
| Supplementary data accompanying this article are available online at www.jpain.org and www.sciencedirect.com. |
Vol 14 - N° 12S
P. T2-T19 - décembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
